
Nanoparticle developer specializing in cancer treatment solutions.
Founded with a mission to revolutionize cancer treatment, Cello Therapeutics specializes in the development of advanced nanoparticle-based therapies. The company focuses on creating innovative nanomedicines designed to enhance the efficacy and reduce the side effects of chemotherapy and immunotherapy. By leveraging cutting-edge technology, Cello aims to provide more effective and targeted cancer treatments, addressing a critical need in the oncology market.
Cello Therapeutics has garnered attention from notable investors and industry experts due to its groundbreaking approach. The company has achieved significant milestones, including securing patents for its proprietary nanoparticle technologies and publishing influential research in leading scientific journals. Cello's impact is marked by its potential to significantly improve cancer treatment outcomes, offering hope to millions of patients worldwide.

Cellics Therapeutics
cellics.com

Nanocan Therapeutics

Telo Therapeutics

PNP Therapeutics

Cellerant Therapeutics

Palm Therapeutics

NanoPharmaceuticals

Cellective BioTherapy

SynerGene Therapeutics

Cellevolve Bio
cellevolve.com

Vali Nanomedical

Advanced NanoTherapies

Nanospectra Biosciences
nanospectra.com

Elucida Oncology

Century Therapeutics
centurytx.com
Companies similar to Cello Therapeutics include Cellics Therapeutics, Nanocan Therapeutics, Telo Therapeutics and PNP Therapeutics.
Cello Therapeutics was founded in 2016.
Cello Therapeutics' headquarters is located in San Diego, CA, US.
Cello Therapeutics' most recent funding round was for $7.1M (USD) in August 2022.
As of Aug 22, 2022, Cello Therapeutics has raised a total of $8.7M (USD).
Cello Therapeutics has 8 employees as of Feb 5, 2024.